Trevena Revenue and Competitors
Estimated Revenue & Valuation
- Trevena's estimated annual revenue is currently $7.5M per year.
- Trevena's estimated revenue per employee is $187,500
- Trevena's total funding is $489.6M.
Employee Data
- Trevena has 40 Employees.
- Trevena grew their employee count by -20% last year.
Trevena's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP, Chief Operating Officer and Chief Financial Officer | Reveal Email/Phone |
3 | SVP, Chief Business Officer and Head Commercial Operations | Reveal Email/Phone |
4 | Principal Financial and Accounting Officer | Reveal Email/Phone |
5 | Area Director | Reveal Email/Phone |
6 | SVP, Chief Business Officer and Head Commercial Operations | Reveal Email/Phone |
7 | Senior Director, Head Discovery and Non-clinical Development | Reveal Email/Phone |
8 | Director Pharmaceutical Development | Reveal Email/Phone |
9 | Associate Director, Human Resources | Reveal Email/Phone |
10 | Key Account Manager | Reveal Email/Phone |
Trevena Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 7 | -12% | N/A | N/A |
#2 | $4M | 38 | 81% | N/A | N/A |
#3 | N/A | 76 | 27% | N/A | N/A |
#4 | $0.9M | 5 | 0% | N/A | N/A |
#5 | $1.1M | 8 | 33% | N/A | N/A |
#6 | $10.9M | 61 | 7% | N/A | N/A |
#7 | $0.7M | 9 | 29% | N/A | N/A |
#8 | $4M | 20 | -5% | N/A | N/A |
#9 | $1.7M | 11 | 22% | N/A | N/A |
#10 | $7.6M | 49 | 2% | N/A | N/A |
What Is Trevena?
Approximately 40% of modern medicinal products target GPCRs and GPCRs remain the largest class of targets currently under clinical evaluation. Currently marketed GPCR drugs suffer significant problems such as limited efficacy and undesirable adverse effects, which generally limit their overall use. Furthermore, there are many GPCRs linked to disease that cannot be translated into medicines because of specific target-related adverse effects. Trevena’s novel drug discovery approach combines a powerful, proprietary and efficient drug discovery platform with the Company’s extensive discovery and development experience to yield a rich pipeline of breakthrough medicines. Trevena’s drug discovery technology is based on the groundbreaking research from the laboratories of leading scientists in the field - Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. of Duke University Medical Center.
keywords:N/A
$489.6M
Total Funding
40
Number of Employees
$7.5M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Trevena News
Trevena Inc. of Chesterbrook received a notice from the NIH that enrollment in the study ceased after an interim analysis of the study data...
Enrollment for Trevena's COVID-19 treatment trial, part of the National Institutes of Health's ACTIV-4 program, has ceased after the program's data safety...
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS...
Other Companies in King of Prussia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.6M | 41 | 8% | N/A |
#2 | $19.1M | 42 | -9% | N/A |
#3 | $15M | 42 | -11% | N/A |
#4 | $9M | 42 | 31% | N/A |
#5 | $11.7M | 43 | 8% | N/A |